Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714739 · ClinicalTrials.gov registry record · Phase 1
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
A Phase 1 study of Cancer, Nos, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 337
- Enrollment target
- 20
- Study locations
NCT01714739: Completed Phase 1 study of Cancer, Nos, sponsored by Bristol-Myers Squibb.
NCT01714739 is a Phase 1 study of Cancer, Nos that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 337 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (462% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714739, a Phase 1 study of Cancer, Nos, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 337 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.
Primary Outcome
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Lirilumab
Study Locations (20)
Massachusetts
- Beth Israel Deaconess Med Ctr - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- UPMC Eye and Ear Institute - Pittsburgh
Texas
- Texas Oncology-Central Austin Cancer Center - Austin
- University Of Texas Medical Branch Of Galveston - Galveston
Ontario
- Juravinski Cancer Center - Hamilton
- Princess Margaret Cancer Centre - Toronto
Other
- Local Institution - Bordeaux
- Local Institution - Lyon
California
- Ucsf - San Francisco
Florida
- Florida Cancer Affiliates - Ocala - Ocala
Illinois
- University Of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2012-10-07 |
| Est. Completion | 2019-12-13 |
| Phase | Phase 1 |
What the finished NCT01714739 record still lists
NCT01714739 is an interventional study that assigns participants to a tested intervention. The registered 337 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (462% higher).
The record links to 1 condition, with Cancer, Nos appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT01714739 names 20 study sites across 14 states, led by Massachusetts, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT01714739 about?
NCT01714739 is a clinical study titled "A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors". To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of l...
What is the current status of trial NCT01714739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 337 participants. The study started on 2012-10-07. Estimated completion is 2019-12-13.
What conditions does trial NCT01714739 study?
This clinical trial studies the following conditions: Cancer, Nos.
What interventions are being tested in trial NCT01714739?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Lirilumab (DRUG).
Who is sponsoring clinical trial NCT01714739?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714739 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer, Nos
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01714739's enrollment target sits among peer trials
337 106th of 2000 higher than 1,895 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI